Aza-bicyclo[3.1.0] hetroaryl amide

Abstract

The present invention relates to a series of substituted bicyclic[3.1.0] heteroaryl amide of the Formula I; wherein R1 represents a heteroaryl selected from the group consisting of imidazolyl, thiazolyl, pyridyl, oxazolyl, pyrazolyl, triazolyl, oxadiazolyl, quinolinyl, isoxazolyl, pyrroloimidazoyl, and thiadiazole, wherein said heteroaryl is optionally substituted by one or more substituents selected from -OH, -NR7R8, halogen, (C1-C8)alkyl, (C3- C 10)cycloalkyl, (C1- C8)alkoxy, (C1 – C12)alkoxyalkyl, (C1- C8)hydroxyalkyl, (C6- C 14)aryl and benzyl; R2, R3 and A independently represent H or (C1-C8)alkyl, wherein said alkyl is optionally substituted by one or more OH, (C1-C8)alkoxy, -NR7R8 or halogen; Q represents -(CH2)n-, where n = 1 , 2, 3 or 4 or -(CH2)m-0-, where m = 2, 3 or 4; Z represents (C6-C14)aryl, (C1-C8)alkyl or (C3-C8)cycloalkyl; R4 and R5 each independently represent H, halogen, (C1-C8)alkyl, (C6-C14)aryl, (C6-C14)aryloxy, (C1-C8)aIkoxy, (3-10 membered) heterocycloalkyl or (C3 C8)cycloalkoxy; wherein R4 and R5 are optionally substituted by one or more OH, (C1-C8)aIkoxy, NR7R8 or halogen; Y represents -R6, -(CH2)o-R6, -C(R6)3 or -CH(R6)2, wherein o = 1, 2 or 3; that exhibit - activity as glycine transport inhibitors, pharmaceutical composition containing its, and its use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.